Abstract
Despite improved supportive care, and the introduction of less toxic lipid-formulations of amphotericin B deoxycholate and other new antifungal agents the mortality from invasive fungal infection (IFI) in hematology patients remains high. New management strategies are therefore required to improve outcome.
Publication types
-
Clinical Trial
-
Letter
-
Multicenter Study
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Amphotericin B / administration & dosage*
-
Amphotericin B / adverse effects
-
Amphotericin B / therapeutic use
-
Antifungal Agents / administration & dosage*
-
Antifungal Agents / adverse effects
-
Antifungal Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Child
-
Female
-
Hematologic Neoplasms / complications
-
Hematologic Neoplasms / drug therapy
-
Hematologic Neoplasms / surgery
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunocompromised Host
-
Kidney Diseases / chemically induced
-
Liposomes / administration & dosage
-
Male
-
Middle Aged
-
Mycoses / drug therapy*
-
Mycoses / etiology
-
Mycoses / mortality
-
Postoperative Complications / drug therapy
-
Postoperative Complications / etiology
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Liposomes
-
liposomal amphotericin B
-
Amphotericin B